Richard Cowan, Cannabis Science CFO, explained, The revenue potential out of this facility is actually very significant, and we’ll make general public our estimates on the projected revenue soon, but, as with our previously announced acquisitions in Colorado and Montana, our main focus shall remain on R&D. As Dr. Melamede has described, previously new biotech companies have never known whether their proposed items were effective and safe until these were submitted for FDA scientific trials. Now Cannabis Science, working in says with medical marijuana laws and regulations, is usually changing the paradigm. We will understand that the products we submit for scientific trials will become what the sufferers want and need. This new facility is an integral part of our corporate technique. .. Cannabis Research enters into long-term lease on 9,500 square foot facility in Denver, Colorado Cannabis Research, Inc.For organ transplantation to save lots of patients with terminal illnesses that is quite effective, says Yang Xu, a professor of biology who headed the group of experts that included Ananda Goldrath, a co-employee biology professor at UC NORTH PARK. But also for stem cell therapies, the future usage of toxic immunosuppressant medicines for sufferers who are getting treated for persistent diseases like Parkinson's disease or diabetes pose serious health issues. Researchers had always been searching for a human being immunity relevant model that could permit them to develop ways of implant allogenic cells produced from embryonic stem cells properly.